AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Agile Therapeutics

Allena Pharmaceuticals

Here's what you need to know about trading penny stocks on July 6th The post What to Know About Buying Penny Stocks on July 7th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on July 7th

Connect Biopharma Holdings

Geron

Can these penny stocks climb this week? The post Hot Penny Stocks That Are Climbing Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks That Are Climbing Right Now

Decibel Therapeautics

Yatsen Holding

Penny stocks to watch before the end of the week. The post Top Penny Stocks Today?

Top Penny Stocks Today? 3 You Might Want To Watch Before Next Week

Liquidia Technologies Inc

TOMI Environmental Solutions

Here's what you need to know about trading penny stocks on June 3rd The post What to Know About Buying Penny Stocks on June 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 3rd

Core Scientific Inc

FuelCell Energy

Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 26th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on May 26th

HAYWARD, Calif., May 20, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for one-on-one meetings throughout the H.C.

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference

The FDA has recently modified the AcelRx Pharmaceuticals Inc's (NASDAQ: ACRX) Dsuvia Risk Evaluation and Mitigation Strategies (REMS) requirements for healthcare setting audits.  The Dsuvia REMS program aims to mitigate the risk of respiratory depression resulting from.

Why AcelRx Pharma Shares Are Trading Higher Today?

HAYWARD, Calif., May 19, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported that the U.S. Food and Drug Administration (FDA) has recently modified the DSUVIA Risk Evaluation and Mitigation Strategies (REMS) requirements with respect to healthcare setting audits.

AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Thomas Yip - H.C. Wainwright Robert LeBoyer - Noble Capital Operator Welcome to the AcelRx First Quarter, 2022 Earnings Call.

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call Transcript

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates

Realigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual savings of $9 million Completed acquisition of Lowell Therapeutics and nafamostat franchise, including Niyad™ with Breakthrough Device Designation  Continued DSUVIA sales momentum with fourth consecutive quarter of sales volume growth, including 64% commercial (ex-DoD) growth in Q1 2022 compared to Q4 2021 $39.3 million of cash and short-term investments at March 31, 2022 Webcast and Conference Call to be held today at 8:30 am EDT HAYWARD, Calif. , May 16, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2022 financial results.

AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Study found that SST lowered the opioid dose required by patients in the post-anesthesia care unit (PACU) by more than five-fold compared to standard intravenous opioid administration HAYWARD, Calif. , May 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of clinical data from an investigator-initiated trial in patients undergoing lengthy plastic surgery procedures performed under general anesthesia, where use of a single sufentanil sublingual tablet 30 mcg (SST; DSUVIA®) in conjunction with intravenous (IV) opioids was able to dramatically reduce postoperative opioid requirements compared to an equivalent dose of opioids administered only via the IV route.

AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia

HAYWARD, Calif. , May 9, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results before market open on Monday, May 16, 2022.

AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022

HAYWARD, Calif. , April 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a summary of results from a podium presentation on DSUVIA® (sufentanil sublingual tablet (SST), 30 mcg) presented at the annual meeting of The Aesthetic Society®, "The Aesthetic Meeting 2022", held from April 20 -24 at the San Diego Convention Center.

Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022

HAYWARD, Calif. , April 21, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming podium presentation on DSUVIA (sufentanil sublingual tablet, 30 mcg) which will be presented at the annual meeting of The Aesthetic Society®, "The Aesthetic Meeting 2022", held from April 20 -24 at the San Diego Convention Center.

AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022

Study results show higher rates of successful procedure completion and higher patient and clinician satisfaction scores compared to topical local anesthesia alone HAYWARD, Calif. , March 31, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study evaluating the use of a sufentanil sublingual tablet (SST) 30 mcg for management of pain of radiofrequency ("RF") microneedling of the face or abdomen.

AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures

Study results demonstrate that nafamostat had similar efficacy as citrate, while providing lower toxicity and lower costs to the hospital over standard citrate anticoagulation. HAYWARD, Calif.

AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q4 2021 Results - Earnings Call Transcript

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 99.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates

HAYWARD, Calif., March 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2021 financial results.

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

HAYWARD, Calif., March 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Thursday, March 10, 2022.

AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022

HAYWARD, Calif., Feb. 1, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of real-world data in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects with the use of sufentanil sublingual tablet (SST) for pain management.

AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures

HAYWARD, Calif., Jan. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of an article reviewing the use of sufentanil sublingual tablet (SST; DSUVIA ® ) for pain medicine procedures by lead author Dr. Sarang Koushik in Current Pain and Headache Reports.

AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures

DSUVIA sales continue to lag expectations. Visibility of earnings and net cash further reduced by Lowell acquisition which is hard to assess at this stage.

AcelRx Pharmaceuticals: The Fog Is Getting Thicker

HAYWARD, Calif., Jan. 12, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of an editorial regarding the use of sufentanil sublingual tablet (SST; DSUVIA®) in total joint replacement surgery by Dr. Scott Sigman in the Journal of Orthopaedic Experience and Innovation.

AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery

News for AcelRx Pharmaceuticals Stock (ACRX)